Business
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported sev
About this update from Merck & Company, Inc.
[{"type":"image","alt":"Arch Biopartners","displaySize":"","headline":null,"caption":"Arch Biopartners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":153,"url":"https://media.zenfs.com/en/globenewswire.com/3720e1c0e58c0ed0ee4a22d619f99f3c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q8ZXiprpWA4grKiyB58dGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3720e1c0e58c0ed0ee4a22d619f99f3c","width":300,"height":153}},"lazy":false},{"type":"text","content":"TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026.","length":256,"tagName":"p"},{"type":"text","content":"Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported several transactions in these roles, including Bruker Corporation’s majority-ownership investment in Biognosys AG in 2023, and Chiesi Farmaceutici’s acquisition of Amryt Pharma later the same year.Dr. Vink previously served as Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, Inc., overseeing global commercial and technical operations until its $9.5 billion acquisition by Merck in 2015. Prior to Cubist, he was Senior Vice President, Global Head of Hospital Business and Biologics for Mylan Inc. (now Viatris Inc.). Earlier in his career, he held senior roles at Novartis Sandoz, Biogen, and Sanofi-Synthelabo. He served as a director of Arch Biopartners from December 2016 until December 2019, and continued to support the Company as a Strategic Advisor thereafter.","length":1042,"tagName":"p"},{"type":"text","content":"“We are happy to have Patrick rejoin the board as our new Chairman during this exciting stage of development for Arch. Patrick’s experience in the pharma industry, combined with his network within the financial markets, will be very helpful to Arch as we advance our acute kidney injury Phase II trials and our chronic kidney disease program,” said Richard Muruvé, CEO of Arch Biopartners.","length":389,"tagName":"p"},{"type":"text","co...